The EDAPT™ Platform
Ervaxx has developed a differentiated technology platform (EDAPT™ - Ervaxx Dark Antigen Platform Technology) designed to explore the new and expanding Dark Antigen™ repertoire, and to identify and assess its tumor specificity and immunogenic potential to combat cancers.
EDAPT™ is a powerful and proprietary approach combining bioinformatics, immunopeptidomics and state-of-the-art T-cell immunology. The platform systematically examines the entire cancer genome to understand changes in transcription patterns and discover and validate previously hidden Dark Antigens™ for use in immunotherapy.
This approach is built upon pioneering research from the Francis Crick Institute, which is being further developed by Ervaxx and advanced through research collaborations with the University of Oxford, University of Cambridge, and Johns Hopkins University School of Medicine.